Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                FDA Voices

FDA Voices Home
          News & Events
          FDA Newsroom
          FDA Voices
          Using A Whole-Of-Governments Approach to Combating Illicit Health ProductsFDA Voices Using A Whole-Of-Governments Approach to Combating Illicit Health Products
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintImage
              Illustration graphic, headline "A Whole-of-Governments approach to combating illicit health products". Left image representing security. Center image world globe. Right image representing supply chain.*By: Cathy Hermsen, Assistant Commissioner for Criminal Investigations and Ritu Nalubola, Director of the FDA’s Europe Office*

Criminal networks are increasingly sophisticated and capable of exploiting regulatory, legal, and other gaps to ship and/or transship illicit and potentially dangerous health products to the U.S., putting patients at risk.

Cathy Hermsen
Cathy HermsenThe variety and scope of the illicit products that the U.S. Food and Administration is witnessing, entering our international mail facilities, has been staggering. The agency has seen medications to treat cancer or chronic diseases such as high blood pressure or diabetes, prescription medical devices, and veterinary drugs. Some products are mislabeled, some are counterfeit. In some cases, we know of products targeted for sale to physicians, that have then been administered to patients, who were unaware these products were being obtained from unauthorized foreign sources and being shipped and stored outside of approved conditions.

In many of these cases, the illicit products have been entering the U.S. marketplace after being shipped to a country in the European Union (EU) first, as an intermediate destination usually without entering customs, a practice known as transshipment. This practice has increased during the COVID-19 pandemic when we saw a surge in fraudulent COVID-19 products – many ordered online and shipped in small packages. For criminal actors, using multiple small shipments instead of larger ones reduces the likelihood of detection and makes it more difficult for authorities to identify the product’s origin or its manufacturer.

Ritu Nalubola
Ritu NalubolaThe U.S. has many protections in place at our ports of entry, including the FDA’s Predictive Risk-based Evaluation for Dynamic Import Compliance Targeting – a risk-based analytics tool that the agency uses to electronically screen all regulated shipments imported or offered for import into the U.S. But when criminals are intent on probing for potential weaknesses, in what amounts to a sophisticated version of whack-a-mole, products can slip through if no one agency can fully thwart these efforts.

A series of successful investigations conducted by the FDA’s Office of Criminal Investigations (OCI) have demonstrated that the best way to address this problem is to cast a wide net by soliciting the help of other parts of the FDA, other U.S. government agencies, and officials in other countries.

For example, since 2017, OCI and the United Kingdom (U.K.) have been engaged in a series of initiatives they call Operation Lascar, which marshals the collective forces of the many U.S. and U.K. agencies that play a role in health care trade, including those involved with customs and border protection, taxation, patent and trademarks protection, and drug regulation.

FDA staff deployed handheld devices at international mail facilities in London that could detect counterfeit drugs. The FDA and the U.K. exchanged import and export customs declaration data and analyzed other current trends. Over the course of five Operation Lascar Initiatives, the FDA originated more than 80 new criminal investigations and identified more than 3,000 violative shipments of illicit medicines intended for the U.S.

However, analysis of recent FDA detentions focused on shipments from the EU suggests that bad actors are now using EU member states as transshipment “hubs” before final shipment to the U.S., likely due to the success of Operation Lascar. This latest practice gives criminals the ability to mask all the prior distribution activity, effectively “restarting” the shipment of illicit products by switching carriers in the EU so that it appears the shipment originated in the EU.

The FDA is now taking the lessons learned from Operation Lascar and other past investigations to promote a whole-of-governments initiative for an effective regional solution. To do so, the agency has partnered with the Organisation of Economic Co-Operation and Development (OECD) Task Force on Countering Illicit Trade, which has been studying the problem of illicit trade for 15 years.

The FDA’s Europe Office and the OECD hosted a nonpublic meeting with officials from 19 countries in May 2022 to introduce the whole-of-governments approach. Counterparts from regulatory, law enforcement, intellectual property, customs, and other relevant government agencies participated in this meeting. Operation Lascar was the first item on the agenda and was lauded as a successful model to emulate.

These government officials met again in July 2022 to discuss illicit products transshipments and trends in the EU and to lay the groundwork for a two-day workshop on September 15-16, 2022, in Paris, organized again by the FDA’s Europe Office and the OECD.

At this workshop, representatives from the public and private sectors will explore regulatory and legal weaknesses and identify potential whole-of-governments solutions. For example, in some countries tax authorities may not be able to easily exchange information with customs or the police, and some nations may take different approaches to illicit goods that may make it more difficult to identify the criminal operators. Additionally, we hope to better understand the roles, responsibilities, and authorities of the various multilateral organizations involved in combating illicit products to determine how best to synergize authorities and quickly shut down illicit trade throughout the supply chain. Industry has a role in these efforts as well and we look forward to their contributions.

A whole-of-governments approach is the best way to protect the public health from the trade of illicit health products and the FDA will advocate for that approach at the September workshop. By having so many parties working together, we hope to effectively close the pipeline of illicit products that are getting through. And with the volume of illicit products growing daily, there’s no time to delay.

                                                                                  Content current as of:
      09/01/2022
              
              
Regulated Product(s)
		 Biologics
			  			     			  			     Dietary Supplements
			     			  			     Drugs
			     			  			     Food & Beverages
			     			  			     Medical DevicesFDA Voices
 FDA Voices Email
                        Subscribe to receive FDA Voices email notifications.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop